Related Experiment Videos
Osteosarcoma of the jaw
R Delgado1, E Maafs, A Alfeiran
1Department of Pathology, Instituto Nacional de Cancerologia of Mexico, Mexico City.
Head & Neck
|May 1, 1994
Summary
Osteogenic sarcoma of the jaw, a rare cancer, has poor survival rates. Tumor size and surgical margins are key prognostic factors, emphasizing the need for early diagnosis.
Area of Science:
- Oncology
- Oral and Maxillofacial Surgery
- Pathology
Background:
- Osteogenic sarcoma of the jaw presents distinct clinical and prognostic features compared to long bone osteosarcomas.
- This study focuses on understanding these differences in a specific patient cohort.
Purpose of the Study:
- To analyze the clinical characteristics, treatment modalities, and prognostic factors of osteogenic sarcoma of the jaw.
- To identify factors influencing survival rates in patients diagnosed with jaw osteosarcoma.
Main Methods:
- Retrospective review of 23 confirmed cases of jaw osteosarcoma diagnosed between 1972 and 1990.
- Data analysis included patient demographics, tumor characteristics, treatment details (surgery, radiotherapy, chemotherapy), and survival outcomes.
Main Results:
- The majority of patients were women (57%), with a median age of 28 years.
- The maxilla was involved in 52% of cases, with a median tumor size of 10x7 cm. Most tumors were high-grade (87% Grade III or IV).
- Five-year survival was low at 10%, with tumor size and surgical margins identified as significant prognostic factors.
Conclusions:
- Tumor size and achieving clear surgical margins are critical prognostic indicators for jaw osteosarcoma.
- Early diagnosis is essential for improving patient survival.
- The specific roles of chemotherapy and radiotherapy in treating this condition require further investigation.